Table 1. People injecting opioids who were infected with the human immunodeficiency virus and received antiretroviral therapy (ART), with or without methadone maintenance treatment (MMT), China, 2002–2011.
| Characteristic | No. (%) of participants |
||
|---|---|---|---|
| All | ART only | ART + MMT | |
| Demographic characteristic | |||
| Age, years | |||
| 15–29 | 4 574 (19.2) | 3 642 (19.5) | 932 (18.1) |
| 30–39 | 14 265 (59.9) | 11 114 (59.6) | 3151 (61.1) |
| ≥ 40 | 4 974 (20.9) | 3 896 (20.9) | 1 078 (20.9) |
| Median (IQR), years | 34.0 (30.0–39.0) | 34.0 (30.0–39.0) | 35.0 (31.0–39.0) |
| Gender | |||
| Male | 20 868 (87.6) | 16 436 (88.1) | 4 432 (85.9) |
| Female | 2 945 (12.4) | 2 216 (11.9) | 729 (14.1) |
| Ethnicity | |||
| Han Chinese | 12 892 (54.1) | 9 555 (51.2) | 3 337 (64.7) |
| Ethnic minority | 8 126 (34.1) | 6 652 (35.7) | 1 474 (28.6) |
| Missing data | 2 795 (11.7) | 2 445 (13.1) | 350 (6.8) |
| Educational level | |||
| Primary school or lower | 8 154 (34.2) | 6 754 (36.2) | 1 400 (27.1) |
| Middle school or higher | 12 416 (52.1) | 9 156 (49.1) | 3 260 (63.2) |
| Missing data | 3 243 (13.6) | 2 742 (14.7) | 501 (9.7) |
| Marital status | |||
| Single, divorced or widowed | 10 796 (45.3) | 7 989 (42.8) | 2 807 (54.4) |
| Married or cohabitating | 12 876 (54.1) | 10 543 (56.5) | 2 333 (45.2) |
| Missing data | 141 (0.6) | 120 (0.6) | 21 (0.4) |
| Clinical characteristic at ART initiation | |||
| CD4+ cell count (cells/µL) | |||
| < 50 | 3 927 (16.5) | 3 359 (18.0) | 568 (11.0) |
| 50–200 | 9 265 (38.9) | 7 157 (38.4) | 2 108 (40.8) |
| > 200 | 9 907 (41.6) | 7 503 (40.2) | 2 404 (46.6) |
| Missing data | 714 (3.0) | 633 (3.4) | 81 (1.6) |
| Median (IQR) | 177.0 (80.0–264.0) | 172.0 (73.0–262.0) | 192.0 (109.5–267.0) |
| Haemoglobin concentration (g/dL) | |||
| < 9 | 1 515 (6.4) | 1 239 (6.6) | 276 (5.3) |
| 9–12 | 5 131 (21.5) | 4 047 (21.7) | 1 084 (21.0) |
| > 12 | 15 485 (65.0) | 11 981 (64.2) | 3 504 (67.9) |
| Missing data | 1 682 (7.1) | 1 385 (7.4) | 297 (5.8) |
| Median (IQR) | 13.4 (11.5–15.0) | 13.4 (11.5–15.1) | 13.4 (11.7–14.8) |
| ART | |||
| Treatment regimen | |||
| Zidovudine, lamivudine and nevirapine or efavirenz | 11 495 (48.3) | 8 890 (47.7) | 2 605 (50.5) |
| Stavudine, lamivudine and nevirapine or efavirenz | 9 271 (38.9) | 7 261 (38.9) | 2 010 (38.9) |
| Other or missing data | 3 047 (12.8) | 2 501 (13.4) | 546 (10.6) |
| Treatment facility | |||
| Infectious disease hospital | 3 739 (15.7) | 2 970 (15.9) | 769 (14.9) |
| General hospital | 15 237 (64.0) | 12 007 (64.4) | 3 230 (62.6) |
| CDC clinic | 3 290 (13.8) | 2 286 (12.3) | 1004 (19.5) |
| Other or missing data | 1 547 (6.5) | 1 389 (7.4) | 158 (3.1) |
| Follow-up status | |||
| Main outcome | |||
| Alive and still on ART | 16 321 (68.5) | 12 590 (67.5) | 3 731 (72.3) |
| Died while on ART | 3 057 (12.8) | 2 519 (13.5) | 538 (10.4) |
| Discontinued ART | 4 435 (18.6) | 3 543 (19.0) | 892 (17.3) |
| Total | 23 813 (100.0) | 18 652 (100.0) | 5 161 (100.0) |
CDC, Chinese Center for Disease Control and Prevention; IQR, interquartile range.
a All values in the table represent absolute numbers and percentages unless otherwise stated.